Why the study?
Does telmisartan provide end-organ protection and reduce cardiovascular risk in patients with high blood pressure?
Does telmisartan provide end-organ protection and reduce cardiovascular risk in patients with high blood pressure?
Telmisartan is an angiotensin receptor blocker with a long duration of action that provides effective blood pressure control and potential end-organ protection.
May support telmisartan for sustained BP control; leaves open superior end-organ protection versus other ARBs.
The principal aim in the treatment of patients with high blood pressure is to ensure a maximum reduction in the total risk of cardiovascular morbidity and mortality. The renin-angiotensin system plays an important role in volume homeostasis and blood pressure regulation. The angiotensin receptor blockers control high blood pressure by preventing the binding of angiotensin II to the subtype 1 receptor, which is believed to mediate most of the physiologic actions of angiotensin II relevant to the regulation of blood pressure. Telmisartan is a widely used angiotensin receptor blocker with distinct pharmacokinetic and pharmacodynamic properties. Due to its long duration of action, it compares favorably with other angiotensin receptor blockers. Latest data from clinical trials and newest research regarding telmisartan will be reviewed in this article.
No takes yet. Share an insight, caveat, or question.
Unger et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: